(Lotte Biologics)

<이미지를 클릭하시면 크게 보실 수 있습니다>

Lotte Biologics Co. said on Thursday it has signed a deal with an Asian biotech firm to manufacture clinical trial materials for antibody-drug conjugates (ADCs), its first contract in the ADC sector. The details about the contractor remain unknown.

The company said the agreement represents the beginning of full-scale operations at its ADC production facility, which has been under expansion since 2023 at the Syracuse Bio Campus in New York.

Lotte Biologics added that it will offer contract development and manufacturing (CDMO) services for ADCs, from clinical development to commercial production, adding that “we plan to seek opportunities to secure additional customers based on this order.”

Lotte Biologics’ ADC production facility has an integrated production and purification line including a conjugation reactor with a capacity of up to 1,000 liters.